Canaccord analyst Kyle Mikson raised the firm’s price target on Grail (GRAL) to $105 from $85 and keeps a Buy rating on the shares. The firm target increase is driven by significant progress/plans to expand adoption levels (and reimbursement) for the Galleri multi-cancer early detection (MCED) test.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
- Grail price target raised to $85 from $38 at Morgan Stanley
- Grail Inc. Navigates Global Trade Challenges Amid Tariffs and Regulatory Hurdles
- Balanced Hold Rating on GRAIL Inc: Navigating Potential and Risks of Galleri’s Multi-Cancer Detection Test
- GRAIL Inc Announces $300M Equity Distribution Agreement
- Grail Inc. Earnings Call: Growth Amid Challenges